USE OF SUBSTITUTED QUINOLONE DERIVATIVES FOR TREATING CANCER
There is provided a novel use of a substituted quinolone compound of the general formula (I), or a pharmaceutically acceptable salt thereof for treatment of cancer. The prepared substituted quinolones with dual anti-inflammation/free radical scavenging and antiproliferation propensities can be used as authentic agents for the treatment of many different types of cancer, particularly skin cancer, breast cancer, lung cancer, prostate cancer, pancreatic cancer, and leukemia. Formula (I) Wherein R1 is selected from OH,OEt,OMe,OPr-n,OPr-i,OBu-n,OBu-i,OBu-s,OBu-t; R2 is selected from (C2 – C10) alkyl, (C3 – C8) cycloalkyl, heteroaryl or heterocycle unsubstituted or substituted; R3 is selected from H, NH2, NO2, OH, OMe, OEt, OPr, OBu, SH, CN, CF3, CCl3, OSO3H, F, Cl, Br, diazonium ion, or linked to NH with (C3-C8) heterocyclic ring; R4 is selected from H, OMe, OH, OEt, OBu, OHx, (C1 – C10) alkyl; R5 is selected from H, OMe, OH, OEt, OBu, OHx, (C1 – C10) alkyl; R6 is selected from H, OH, OMe, OEt, OBu, OHx,(C1 – C10) alkyl; R4, R5, R6 are mono-, di-, or tri- substituted with H, OMe, OH, OEt, OBu, OHx, (C1 – C10) alkyl; and X is selected from fluorine, chlorine, or hydrogen atom..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 14. Sept. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
AL-KUBAISI MOHAMMED AMEEN FOUAD SALEH [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-09-14, Last update posted on www.tib.eu: 2024-02-06, Last updated: 2024-02-09 |
|---|
| Patentnummer: |
WO2023170724 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018149324 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018149324 | ||
| 003 | DE-627 | ||
| 005 | 20240209083044.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231006s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018149324 | ||
| 035 | |a (EPA)WO2023170724 | ||
| 035 | |a (EPA)87936328 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a AL-KUBAISI MOHAMMED AMEEN FOUAD SALEH |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a USE OF SUBSTITUTED QUINOLONE DERIVATIVES FOR TREATING CANCER |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-09-14, Last update posted on www.tib.eu: 2024-02-06, Last updated: 2024-02-09 | ||
| 520 | |a There is provided a novel use of a substituted quinolone compound of the general formula (I), or a pharmaceutically acceptable salt thereof for treatment of cancer. The prepared substituted quinolones with dual anti-inflammation/free radical scavenging and antiproliferation propensities can be used as authentic agents for the treatment of many different types of cancer, particularly skin cancer, breast cancer, lung cancer, prostate cancer, pancreatic cancer, and leukemia. Formula (I) Wherein R1 is selected from OH,OEt,OMe,OPr-n,OPr-i,OBu-n,OBu-i,OBu-s,OBu-t; R2 is selected from (C2 – C10) alkyl, (C3 – C8) cycloalkyl, heteroaryl or heterocycle unsubstituted or substituted; R3 is selected from H, NH2, NO2, OH, OMe, OEt, OPr, OBu, SH, CN, CF3, CCl3, OSO3H, F, Cl, Br, diazonium ion, or linked to NH with (C3-C8) heterocyclic ring; R4 is selected from H, OMe, OH, OEt, OBu, OHx, (C1 – C10) alkyl; R5 is selected from H, OMe, OH, OEt, OBu, OHx, (C1 – C10) alkyl; R6 is selected from H, OH, OMe, OEt, OBu, OHx,(C1 – C10) alkyl; R4, R5, R6 are mono-, di-, or tri- substituted with H, OMe, OH, OEt, OBu, OHx, (C1 – C10) alkyl; and X is selected from fluorine, chlorine, or hydrogen atom. | ||
| 650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ALHIARI YUSUF |4 aut | |
| 700 | 0 | |a KASABRI VIOLET |4 aut | |
| 700 | 0 | |a DARWISH RULA |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 14. Sept. |
| 773 | 1 | 8 | |g year:2023 |g day:14 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/87936328/publication/WO2023170724A1?q=WO2023170724 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 14 |c 09 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 14 |c 09 | ||